Risk of Hypospadias in Newborn Infants Exposed to Valproic Acid During the First Trimester of Pregnancy

AbstractBackground: Hypospadias is one of the most frequently occurring genital anomalies described in infants prenatally exposed to valproic acid (VA). However, to our knowledge, only one publication has studied a potential causal relationship between VA and hypospadias, only estimating the unadjusted global risk. Here we present the results of a multivariate case-control study aimed at analysing and quantifying the specific risk of hypospadias in newborn infants exposed to VA during the first trimester of pregnancy. Methods: The data analysed here were derived from the Spanish Collaborative Study of Congenital Malformations (ECEMC), an ongoing, hospital-based, case-control study and surveillance system in which collaborating paediatricians identify case and control infants. The paediatricians collect the same data for both case and control infants, blinded to information on any prenatal exposure. The information includes 312 items related to many prenatal exposures, including drug exposure, reproductive and family history, and other characteristics. The sample analysed included 2393 infants with hypospadias and 12 465 male controls. Results: The results showed that the unadjusted risk of hypospadias in infants prenatally exposed to VA was 5.23 (95% CI 2.31, 11.86; p < 0.00001). Once adjusted for 13 potential confounding factors using conditional logistic regression analyses, the value of the risk was of a similar magnitude (odds ratio = 5.71; 95% I 1.78, 18.36; p = 0.003). In addition, the frequency of hypospadias in the study population was approximately 1.8/1000 births. This allowed us to calculate the specific risk for an infant with hypospadias to be born to an exposed mother, which was 1 child in 97 births to mothers using VA during the first trimester of pregnancy. We consider this information much more useful for risk assessment than the risk value itself. Conclusions: An alteration of placental gonadotrophic stimulation caused by changes in gonadotropin-releasing hormone release produced by the effects of VA on GABA is a possible pathogenic mechanism. Our results support the relationship between prenatal exposure to VA and hypospadias.

[1]  M. Martinez-frias,et al.  Postmarketing Analysis of Medicines , 2012, Drug safety.

[2]  B. A. Lond,et al.  Andrew Moynihan Claye. , 1977, Lancet.

[3]  M. Martinez-frias,et al.  Case-control studies using only malformed infants: are we interpreting the results correctly? , 1999, Teratology.

[4]  M. Martínez‐Frías Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. , 1990, American journal of medical genetics.

[5]  P. Licht,et al.  Evidence for a modulation of human chorionic gonadotropin (hCG) subunit messenger ribonucleic acid levels and hCG secretion by gamma-aminobutyric acid in human first trimester placenta in vitro. , 1992, Endocrinology.

[6]  A. Czeizel,et al.  VALPROIC ACID AND SPINA BIFIDA , 1982, The Lancet.

[7]  S. Clarren,et al.  Verification of the fetal valproate syndrome phenotype. , 1988, American journal of medical genetics.

[8]  Lammer Ej,et al.  Teratogen update: valproic acid. , 1987, Teratology.

[9]  B. Källén,et al.  Anticonvulsant drugs in monotherapy. Effect on the fetus , 1987, European Journal of Epidemiology.

[10]  Evans Da Letter: Coeliac disease and HL-A8. , 1973 .

[11]  Wells Wt Definition of insanity. , 1984 .

[12]  G. Zampino,et al.  Teratogenic Effects of Antiepileptic Drugs: Use of an International Database on Malformations and Drug Exposure (MADRE) , 2000, Epilepsia.

[13]  J. Chen [Transferrin subtypes in 11 south China minority populations]. , 1992, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[14]  R. Winter,et al.  Fetal valproate syndrome: is there a recognisable phenotype? , 1987, Journal of medical genetics.

[15]  H. Nau,et al.  Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. , 1986, The Journal of pediatrics.

[16]  D. Heber,et al.  Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen. , 1985, The Journal of clinical endocrinology and metabolism.

[17]  L. Holmes,et al.  Increased rate of major malformations in offspring exposed to valproate during pregnancy , 2005, Neurology.

[18]  I. Arroyo,et al.  Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. , 2000, American journal of medical genetics.

[19]  C. Curry,et al.  The fetal valproate syndrome. , 1984, American journal of medical genetics.

[20]  J. Grotta,et al.  Prevention of stroke with ticlopidine , 1992, Neurology.

[21]  P. Oakeshott,et al.  VALPROATE AND SPINA BIFIDA , 1989, The Lancet.

[22]  E. Robert,et al.  [Prenatal ultrasonographic diagnosis in the epileptic mother on valproic acid. Retrospective study of 161 cases in the central eastern France register of congenital malformations]. , 1998, Journal de gynecologie, obstetrique et biologie de la reproduction.

[23]  M. Martinez-frias,et al.  Case-control studies using only malformed infants who were prenatally exposed to drugs. What do the results mean? , 2000, Teratology.

[24]  E. Robert,et al.  MATERNAL VALPROIC ACID AND CONGENITAL NEURAL TUBE DEFECTS , 1982, The Lancet.

[25]  D. Lindhout,et al.  Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. , 1992, Neurology.

[26]  B. Källén Valproic acid is known to cause hypospadias in man but does not reduce anogenital distance or causes hypospadias in rats. , 2008, Basic & clinical pharmacology & toxicology.

[27]  M. Martinez-frias,et al.  Interviewer bias and maternal bias. , 1993, Teratology.